Agonists and antagonists of protease activated receptors (PARs)

被引:57
作者
Barry, GD [1 ]
Le, GT [1 ]
Fairlie, DP [1 ]
机构
[1] Univ Queensland, Ctr Drug Design & Dev, Inst Mol Biosci, Brisbane, Qld 4072, Australia
关键词
GPCR; PAR; protease; review; agonist; antagonist; thrombin; trypsin;
D O I
10.2174/092986706775476070
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Protease activated receptors (PARs) are a category of G-protein coupled receptors (GPCRs) implicated in the progression of a wide range of diseases, including thrombosis, inflammatory disorders, and proliferative diseases. Signal transduction via PARs proceeds via an unusual activation mechanism. Instead of being activated through direct interaction with an extracellular signal like most GPCRs. they are self-activated following cleavage of their extracellular N-terminus by serine proteases to generate a new receptor N-terminus that acts as an intramolecular ligand by folding back onto itself and triggering receptor activation. Short synthetic peptides corresponding to this newly exposed N-terminal tethered ligand can activate three of the four known PARs in the absence of proteases. and such PAR activating peptides (PAR-APs) have served as templates for agonist/antagonist development. In fact much of the evidence for involvement of PARs in diseases has relied upon use of PAR-APs. often of low potency and uncertain selectivity. This review summarizes current structures of PAR agonists and antagonists, the need for more selective and more potent PAR ligands that activate or antagonize this intriguing class of receptors, and outlines the background relevant to PAR activation, assay methods, and physiological properties anticipated for PAR ligands.
引用
收藏
页码:243 / 265
页数:23
相关论文
共 200 条
[1]   Expression of protease-activated receptor-2 by osteoblasts [J].
Abraham, LA ;
Chinni, C ;
Jenkins, AL ;
Lourbakos, A ;
Ally, N ;
Pike, RN ;
Mackie, EJ .
BONE, 2000, 26 (01) :7-14
[2]   Modulation of osteoblast-like-cell behavior by activation of protease activated receptor-1 [J].
Abraham, LA ;
Mackie, EJ .
JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 (08) :1320-1329
[3]   Binding of a thrombin receptor tethered ligand analogue to human platelet thrombin receptor [J].
Ahn, HS ;
Foster, C ;
Boykow, G ;
Arik, L ;
SmithTorhan, A ;
Hesk, D ;
Chatterjee, M .
MOLECULAR PHARMACOLOGY, 1997, 51 (02) :350-356
[4]   Structure-activity relationships of pyrroloquinazolines as thrombin receptor antagonists [J].
Ahn, HS ;
Arik, L ;
Boykow, G ;
Burnett, DA ;
Caplen, MA ;
Czarniecki, M ;
Domalski, MS ;
Foster, C ;
Manna, M ;
Stamford, AW ;
Wu, YS .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (14) :2073-2078
[5]   Inhibition of cellular action of thrombin by N3-cyclopropyl-7-{[4-(1-methylethyl)phenyl]methyl}-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine (SCH 79797), a nonpeptide thrombin receptor antagonist [J].
Ahn, HS ;
Foster, C ;
Boykow, G ;
Stamford, A ;
Manna, M ;
Graziano, M .
BIOCHEMICAL PHARMACOLOGY, 2000, 60 (10) :1425-1434
[6]   Proteinase-activated receptor-2: Key role of amino-terminal dipeptide residues of the tethered ligand for receptor activation [J].
Al-Ani, B ;
Hansen, KK ;
Hollenberg, MD .
MOLECULAR PHARMACOLOGY, 2004, 65 (01) :149-156
[7]   Modified proteinase-activated receptor-1 and-2 derived peptides inhibit proteinase-activated receptor-2 activation by trypsin [J].
Al-Ani, B ;
Saifeddine, M ;
Wijesuriya, SJ ;
Hollenberg, MD .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 300 (02) :702-708
[8]   Proteinase-activated receptor 2: Differential activation of the receptor by tethered ligand and soluble peptide analogs [J].
Al-Ani, B ;
Wijesuriya, SJ ;
Hollenberg, MD .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 302 (03) :1046-1054
[9]  
Al-Ani B, 1999, J PHARMACOL EXP THER, V290, P753
[10]  
ALANIB, 2002, J PHARMACOL EXP THER, V302, P1046